Pfizer, Inc.: Beat — EPS $0.87, Revenue $16.58B
Earnings BeatQ3 2026 · Pre-market
Did Pfizer, Inc. (PFE) beat earnings today?
Yes, Pfizer, Inc. (PFE) beat Wall Street analyst expectations for Q3 2026, reporting higher-than-expected EPS and higher-than-expected revenue.
Earnings Per Share+19.18% surprise
$0.87Actual
Expected: $0.73
vs. year ago +0.0%
Total Revenue+4.43% surprise
$16.58BActual
Expected: $15.88B
vs. year ago -0.4%
Released Nov 03 · 6:45 AM ET
Earning Report
| Metric | Q3 2026 | Q3 2025 | YoY Change % |
|---|---|---|---|
| Revenue | $16.58B | $16.65B | -0.4% |
| Revenue detail — reported lines | |||
| └─Biopharma | $16.28B | $16.31B | -0.2% |
| └─Pfizer CentreOne | $300.00M | $344.00M | -12.8% |
| Net Income | $3.24B | $3.54B | -8.0% |
| Reported Diluted EPS | $0.56 | $0.62 | -9.0% |
| Adjusted Diluted EPS | $0.87 | $0.87 | +0.0% |
Financial Outlook / Guidance
| Metric | FY26 Outlook | |
|---|---|---|
| Guidance | Expected | |
| Revenues | $62.0B-$64.0B (prev. $60.5B-$62.5B) | $62.23BIn-Line |
| Adjusted SI&A Expenses | $12.5B-$13.5B | — |
| Adjusted R&D Expenses | $10.8B-$11.8B (prev. $10.5B-$11.5B) | — |
| Adjusted Diluted EPS | $2.95-$3.05 (prev. $2.80-$3.00) | $2.96In-Line |
FY26 Outlook
- Revenues
- Guidance$62.0B-$64.0B(prev. $60.5B-$62.5B)Expected$62.23BIn-Line
- Adjusted SI&A Expenses
- Guidance$12.5B-$13.5BExpected—
- Adjusted R&D Expenses
- Guidance$10.8B-$11.8B(prev. $10.5B-$11.5B)Expected—
- Adjusted Diluted EPS
- Guidance$2.95-$3.05(prev. $2.80-$3.00)Expected$2.96In-Line
Business Highlights
- ➤FDA approved the 2026-2027 Comirnaty formula for specified higher-risk populations.
- ➤Elrexfio Phase 3 MagnetisMM-32 met its progression-free survival primary endpoint.
- ➤Litfulo Phase 3 trials showed improved repigmentation in nonsegmental vitiligo at Week 52.
- ➤FDA expanded Talzenna plus Xtandi for HRR-mutated metastatic prostate cancer.
- ➤FDA approved Tukysa combination maintenance therapy for HER2-positive metastatic breast cancer.
- ➤25vPnC infant Phase 2 data supported the ongoing Phase 3 program.
- ➤EMA validated the Lyme vaccine candidate marketing authorization application.
- ➤The Phase 3 pivotal program for tilrekimig is underway in atopic dermatitis and asthma.
- ➤Cecile Guegan became Chief Financial Officer and Executive Vice President effective November 1, 2026.
- ➤No share repurchases were completed in 2026; $3.3B authorization remained November 3.
Management Commentary
Dr. Albert Bourla, Chairman and CEO of Pfizer
“Pfizer had another strong quarter with commercial momentum and disciplined execution while advancing our strategy for creating long-term shareholder value. Our obesity program continued to advance and recent milestones in oncology, immunology and vaccines further demonstrate the potential of our pipeline. With a robust slate of expected catalysts ahead, I believe we're well positioned to deliver meaningful new medicines for patients and lasting value in the years ahead.”
Cecile Guegan, CFO and EVP of Pfizer
“Our third-quarter results reflect strong commercial performance globally and continued operational discipline. This quarter, our non-COVID products delivered strong 7% operational revenue growth, and I’m particularly pleased with the 32% year-over-year operational revenue growth from our launched and acquired products((1)). Today, we are raising our full-year 2026 Revenue and Adjusted diluted EPS guidance, reflecting our strong year-to-date performance and confidence in our business.”